优赫得在华获批新适应症

南方财经网01-22

南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得®（英文商品名：Enhertu®，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。（21...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605696344?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-22 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605696344","market":"sh","top_or_hot":-1,"title":"优赫得在华获批新适应症","media":"南方财经网","content":"<div>\n<p>南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得®（英文商品名：Enhertu®，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。（21...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202601223627420221.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>优赫得在华获批新适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n优赫得在华获批新适应症\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-22 16:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202601223627420221.html><strong>南方财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得®（英文商品名：Enhertu®，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。（21...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202601223627420221.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADC","symbol_name":"艾格里房产","start_time":0,"source_url":"http://finance.eastmoney.com/a/202601223627420221.html","article_id":"2605696344","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605696344","pubTimestamp":1769071572,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得?（英文商品名：Enhertu?，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ADC":"艾格里房产","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托"},"translate_title":"Youhede approved for new indications in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1},"content_text":"南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得®（英文商品名：Enhertu®，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。（21世纪经济报道） （文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605696344","isCrawlerRequest":true}